DK1816121T3 - 9-chlor-15-deoxyprostaglandinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som medikamenter - Google Patents

9-chlor-15-deoxyprostaglandinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som medikamenter

Info

Publication number
DK1816121T3
DK1816121T3 DK05090321T DK05090321T DK1816121T3 DK 1816121 T3 DK1816121 T3 DK 1816121T3 DK 05090321 T DK05090321 T DK 05090321T DK 05090321 T DK05090321 T DK 05090321T DK 1816121 T3 DK1816121 T3 DK 1816121T3
Authority
DK
Denmark
Prior art keywords
medicaments
chloro
preparation
deoxyprostaglandin
derivatives
Prior art date
Application number
DK05090321T
Other languages
Danish (da)
English (en)
Inventor
Judy Li
Werner Skuballa
Bernd Buchmann
Bernhard Lindenthal
Gernot Langer
Luisella Toschi
William J Guilford
Daryl Faulds
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of DK1816121T3 publication Critical patent/DK1816121T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
DK05090321T 2005-11-21 2005-11-21 9-chlor-15-deoxyprostaglandinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som medikamenter DK1816121T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05090321A EP1816121B1 (de) 2005-11-21 2005-11-21 9-Chloro-15-deoxyprostaglandinderivate, Verfahren zu ihrer Herstellung und deren Verwendung als Medikamente

Publications (1)

Publication Number Publication Date
DK1816121T3 true DK1816121T3 (da) 2008-06-16

Family

ID=35744724

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05090321T DK1816121T3 (da) 2005-11-21 2005-11-21 9-chlor-15-deoxyprostaglandinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som medikamenter

Country Status (25)

Country Link
EP (1) EP1816121B1 (de)
JP (1) JP2009516665A (de)
KR (1) KR20080068877A (de)
CN (1) CN101312946A (de)
AR (1) AR057900A1 (de)
AT (1) ATE388936T1 (de)
AU (1) AU2006314733A1 (de)
BR (1) BRPI0618756A2 (de)
CA (1) CA2629031A1 (de)
CR (1) CR10006A (de)
DE (1) DE602005005355T2 (de)
DK (1) DK1816121T3 (de)
DO (1) DOP2006000257A (de)
EA (1) EA200801211A1 (de)
EC (1) ECSP088472A (de)
ES (1) ES2302122T3 (de)
GT (1) GT200800066A (de)
IL (1) IL190596A0 (de)
NO (1) NO20082838L (de)
PE (1) PE20070644A1 (de)
PL (1) PL1816121T3 (de)
PT (1) PT1816121E (de)
TW (1) TW200738611A (de)
UY (1) UY29925A1 (de)
WO (1) WO2007057232A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5271272B2 (ja) * 2006-11-16 2013-08-21 ジェンムス ファーマ インコーポレイティド Ａ型インフルエンザウィルス感染の治療のための薬剤としてのｅｐ２およびｅｐ４作動薬
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
AU2021220877A1 (en) 2020-02-12 2022-09-01 Cytoagents, Inc. Compositions and methods for treating coronavirus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171331A (en) * 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
DE2950027A1 (de) * 1979-12-10 1981-06-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin 9-chlor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel
JP3162668B2 (ja) * 1997-02-04 2001-05-08 小野薬品工業株式会社 ω−シクロアルキル−プロスタグランジンＥ２誘導体
JP2000095755A (ja) * 1998-07-21 2000-04-04 Ono Pharmaceut Co Ltd ω―シクロアルキル―プロスタグランジンＥ１誘導体、その製造方法およびその誘導体を有効成分とする医薬組成物
EP1306087A4 (de) * 2000-07-31 2007-07-25 Ono Pharmaceutical Co Heilmittel zur behandlung von erektionsstörungen enthaltend prostaglandinderivate als aktive komponenten

Also Published As

Publication number Publication date
JP2009516665A (ja) 2009-04-23
PE20070644A1 (es) 2007-07-31
EP1816121A1 (de) 2007-08-08
AU2006314733A1 (en) 2007-05-24
IL190596A0 (en) 2008-11-03
PT1816121E (pt) 2008-05-28
CR10006A (de) 2008-07-29
ATE388936T1 (de) 2008-03-15
DE602005005355D1 (de) 2008-04-24
TW200738611A (en) 2007-10-16
UY29925A1 (es) 2007-06-29
GT200800066A (es) 2009-03-12
PL1816121T3 (pl) 2008-08-29
KR20080068877A (ko) 2008-07-24
BRPI0618756A2 (pt) 2011-09-13
CN101312946A (zh) 2008-11-26
DE602005005355T2 (de) 2009-03-26
ECSP088472A (es) 2008-06-30
EP1816121B1 (de) 2008-03-12
ES2302122T3 (es) 2008-07-01
NO20082838L (no) 2008-06-20
EA200801211A1 (ru) 2008-10-30
AR057900A1 (es) 2007-12-26
WO2007057232A1 (en) 2007-05-24
DOP2006000257A (es) 2007-06-15
CA2629031A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
DK1711494T3 (da) Arylsubstituerede heterocykler, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
DK1670458T3 (da) 1-Amino-2-oxy-substituerede tetrahydronaphthalenderivater, fremgangsmåder til fremstilling deraf og deres anvendelse som antiphlogistika
DK1730131T3 (da) Glucopyranosyl-substituerede benzol-derivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
DK2044076T3 (da) Fremgangsmåde til fremstilling af asenapin og intermediatprodukter, som anvendes i fremgangsmåden
DK2024352T3 (da) Glucopyranosylsubstituerede benzoenitrilderivater, farmaceutiske sammensætninger indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde for deres fremstilling
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
DK1948149T4 (da) Formulering, som omfatter metformin og vildagliptin
DK2178881T3 (da) Hidtil ukendte 6-triazolopyridazin-sulfanyl-benzothiazol- og -benzimidazolderivater, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler og farmaceutiske sammensætninger og hidtil ukendt anvendelse som met-hæmmere
NO20054220D0 (no) Substituerte N-arylheterocykler, fremgangsmate for fremstilling derav og deres anvendelse som legemiddel
DK2051975T3 (da) Substituerede prolinamider, fremstilling deraf og anvendelse deraf som lægemiddel.
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
LTC1907382I2 (lt) Nitrokatechnolio dariniai, kaip COMT inhibitoriai
DK1904475T3 (da) N-thioanthranilamid-forbindelser og deres anvendelse som pesticider
DK1928840T3 (da) 1H-pyrazol-4-carboxamider, deres fremstilling og deres anvendelse som 11-beta-hydroxysteroid-dehydrogenaseinhibitorer
DK1960352T3 (da) 2-adamantylurinstof-derivater som selektive 11beta-hsd1 inhibitorer
NO20082793L (no) Nye tiofenderivater
NO20054905D0 (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
DK1888595T3 (da) Spiro-oxindolforbindelser og deres anvendelser som terapeutiske midler
DK2229360T3 (da) Indolinonderivater og fremgangsmåde til deres fremstilling
DK1846394T3 (da) Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
DK2041069T3 (da) Benzylaminer, fremgangsmåde til fremstilling deraf og deres anvendelse som anti-inflammatoriske midler
DK2350026T3 (da) Sulfoximinsubstituerede anilinopyrimidinderativer som cdk-inhibitorer, fremstilling og anvendelse heraf som lægemiddel
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
DK1994005T3 (da) Tetrahydronaphthalinderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelseshæmmere
DK2240482T3 (da) Cykliske azaindol-3-carboxamider, deres fremstilling og deres anvendelse som lægemidler